These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

355 related articles for article (PubMed ID: 32699149)

  • 21. Anakinra in COVID-19 therapy: what have we learned from adult-onset Still's disease?
    Bilia S; Giannini D; Rizzelli GML; Tavoni A
    Clin Exp Rheumatol; 2020; 38(3):579. PubMed ID: 32456767
    [No Abstract]   [Full Text] [Related]  

  • 22. Outcomes and biomarker analyses among patients with COVID-19 treated with interleukin 6 (IL-6) receptor antagonist sarilumab at a single institution in Italy.
    Montesarchio V; Parrela R; Iommelli C; Bianco A; Manzillo E; Fraganza F; Palumbo C; Rea G; Murino P; De Rosa R; Atripaldi L; D'Abbraccio M; Curvietto M; Mallardo D; Celentano E; Grimaldi AM; Palla M; Trojaniello C; Vitale MG; Million-Weaver SL; Ascierto PA
    J Immunother Cancer; 2020 Aug; 8(2):. PubMed ID: 32784217
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The Role of Inflammatory Cytokines (Interleukin-1 and Interleukin-6) as a Potential Biomarker in the Different Stages of COVID-19 (Mild, Severe, and Critical).
    Ghofrani Nezhad M; Jami G; Kooshkaki O; Chamani S; Naghizadeh A
    J Interferon Cytokine Res; 2023 Apr; 43(4):147-163. PubMed ID: 37062817
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Biomarker-guided application of low-dose anakinra in an acute respiratory distress syndrome patient with severe COVID-19 and cytokine release syndrome.
    Steinhardt MJ; Wiebecke S; Weismann D; Frantz S; Tony HP; Klinker H; Schmalzing M
    Scand J Rheumatol; 2020 Sep; 49(5):414-416. PubMed ID: 32914670
    [No Abstract]   [Full Text] [Related]  

  • 25. Characteristics of patients with COVID-19 pneumonia at Hvidovre Hospital, March-April 2020.
    Israelsen SB; Kristiansen KT; Hindsberger B; Ulrik CS; Andersen O; Jensen M; Andersen S; Rasmussen C; Jørgensen HL; Østergaard C; Lindhardt BØ; Kronborg G; Benfield T
    Dan Med J; 2020 May; 67(6):. PubMed ID: 32448405
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Immunothrombotic Dysregulation in COVID-19 Pneumonia Is Associated With Respiratory Failure and Coagulopathy.
    Nicolai L; Leunig A; Brambs S; Kaiser R; Weinberger T; Weigand M; Muenchhoff M; Hellmuth JC; Ledderose S; Schulz H; Scherer C; Rudelius M; Zoller M; Höchter D; Keppler O; Teupser D; Zwißler B; von Bergwelt-Baildon M; Kääb S; Massberg S; Pekayvaz K; Stark K
    Circulation; 2020 Sep; 142(12):1176-1189. PubMed ID: 32755393
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cytokine profile in plasma of severe COVID-19 does not differ from ARDS and sepsis.
    Wilson JG; Simpson LJ; Ferreira AM; Rustagi A; Roque J; Asuni A; Ranganath T; Grant PM; Subramanian A; Rosenberg-Hasson Y; Maecker HT; Holmes SP; Levitt JE; Blish CA; Rogers AJ
    JCI Insight; 2020 Sep; 5(17):. PubMed ID: 32706339
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A Patient with Cryoglobulinemic Membranoproliferative GN (MPGN) Who Survived COVID-19 Disease: Case Presentation and Current Data of COVID-19 Infection in Dialysis and Transplanted Patients in Greece.
    Marinaki S; Tsiakas S; Skalioti C; Lourida P; Argyraki A; Grigorakos K; Boletis I
    Medicina (Kaunas); 2020 Jul; 56(7):. PubMed ID: 32708858
    [TBL] [Abstract][Full Text] [Related]  

  • 29. COVID-19, Medication-Assisted Treatment, and Increased Risk for Further Respiratory Depression.
    Boyer J
    Am J Psychiatry; 2020 Jul; 177(7):636. PubMed ID: 32605451
    [No Abstract]   [Full Text] [Related]  

  • 30. Cyclosporine A: a valid candidate to treat COVID-19 patients with acute respiratory failure?
    Cour M; Ovize M; Argaud L
    Crit Care; 2020 Jun; 24(1):276. PubMed ID: 32487139
    [No Abstract]   [Full Text] [Related]  

  • 31. Anakinra in hospitalized patients with severe COVID-19 pneumonia requiring oxygen therapy: Results of a prospective, open-label, interventional study.
    Balkhair A; Al-Zakwani I; Al Busaidi M; Al-Khirbash A; Al Mubaihsi S; BaTaher H; Al Aghbari J; Al Busaidi I; Al Kindi M; Baawain S; Al Alawi A; Al Lawati A; Al Rawahi B; Al-Baimani K; Al Zidi K; Elfatih N; Dawud B; John B; Rehman F; Yousif F; Al Khadouri G; Saber I; Lal J; Gargouri M; Al-Ward M; AbuDraz N; Al Ruqeishi S; Kumar S; Abdelmottaleb W; Al-Naamani Z; Bin Nazar Z; Balkhair O
    Int J Infect Dis; 2021 Feb; 103():288-296. PubMed ID: 33217576
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Respiratory Impairment Predicts Response to IL-1 and IL-6 Blockade in COVID-19 Patients With Severe Pneumonia and Hyper-Inflammation.
    Della-Torre E; Lanzillotta M; Campochiaro C; Cavalli G; De Luca G; Tomelleri A; Boffini N; De Lorenzo R; Ruggeri A; Rovere-Querini P; Castagna A; Landoni G; Tresoldi M; Ciceri F; Zangrillo A; Dagna L
    Front Immunol; 2021; 12():675678. PubMed ID: 33995419
    [TBL] [Abstract][Full Text] [Related]  

  • 33. IL-1 Receptor Antagonist Anakinra in the Treatment of COVID-19 Acute Respiratory Distress Syndrome: A Retrospective, Observational Study.
    Franzetti M; Forastieri A; Borsa N; Pandolfo A; Molteni C; Borghesi L; Pontiggia S; Evasi G; Guiotto L; Erba M; Pozzetti U; Ronchetti A; Valsecchi L; Castaldo G; Longoni E; Colombo D; Soncini M; Crespi S; Maggiolini S; Guzzon D; Piconi S
    J Immunol; 2021 Apr; 206(7):1569-1575. PubMed ID: 33547169
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Interleukin-1 blockade with high-dose anakinra in patients with COVID-19, acute respiratory distress syndrome, and hyperinflammation: a retrospective cohort study.
    Cavalli G; De Luca G; Campochiaro C; Della-Torre E; Ripa M; Canetti D; Oltolini C; Castiglioni B; Tassan Din C; Boffini N; Tomelleri A; Farina N; Ruggeri A; Rovere-Querini P; Di Lucca G; Martinenghi S; Scotti R; Tresoldi M; Ciceri F; Landoni G; Zangrillo A; Scarpellini P; Dagna L
    Lancet Rheumatol; 2020 Jun; 2(6):e325-e331. PubMed ID: 32501454
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prediction of Survival by IL-6 in a Randomized Placebo-Controlled Trial of Anakinra in COVID-19 Cytokine Storm.
    Jackson LE; Khullar N; Beukelman T; Chapleau C; Kamath A; Cron RQ; Chatham WW
    Viruses; 2023 Sep; 15(10):. PubMed ID: 37896812
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Vitamin D can prevent COVID-19 infection-induced multiple organ damage.
    Aygun H
    Naunyn Schmiedebergs Arch Pharmacol; 2020 Jul; 393(7):1157-1160. PubMed ID: 32451597
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Anakinra for the Treatment of COVID-19-Associated Pericarditis: A Case Report.
    Karadeniz H; Yamak BA; Özger HS; Sezenöz B; Tufan A; Emmi G
    Cardiovasc Drugs Ther; 2020 Dec; 34(6):883-885. PubMed ID: 32734502
    [No Abstract]   [Full Text] [Related]  

  • 38. [Proposal for the use of anakinra in acute respiratory distress secondary to COVID-19].
    Muñoz-Jiménez A; Rubio-Romero E; Marenco de la Fuente JL
    Reumatol Clin (Engl Ed); 2021; 17(6):309-312. PubMed ID: 32482538
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Photodynamic and sonodynamic therapy of acute hypoxemic respiratory failure in patients with COVID-19.
    Kipshidze N; Yeo N; Kipshidze N
    Photodiagnosis Photodyn Ther; 2020 Sep; 31():101961. PubMed ID: 32818638
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Current evidence on the use of anakinra in COVID-19.
    Khani E; Shahrabi M; Rezaei H; Pourkarim F; Afsharirad H; Solduzian M
    Int Immunopharmacol; 2022 Oct; 111():109075. PubMed ID: 35905562
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.